发明名称 |
Protease activity of thrombin inhibits angiogenesis |
摘要 |
The present invention features pharmaceutical compositions and methods to inhibit angiogenesis, with implications to cancer therapy. These methods are based on the discovery that activated thrombin has antiangiogenic activity and that this antiangiogenic activity is at least in part, mediated through the activation of a class of thrombin receptors termed, Protease Activated Receptor (PAR). Pharmaceutical compositions and methods are also directed to a class of proteases which mediate this activation, particularly the urokinase plasminogen activator (uPA) polypeptide. |
申请公布号 |
AU2003218213(A8) |
申请公布日期 |
2003.10.08 |
申请号 |
AU20030218213 |
申请日期 |
2003.03.14 |
申请人 |
BETH ISRAEL DEACONESS MEDICAL CENTER |
发明人 |
VIKAS P. SUKHATME;JAIME MERCHAN;BARDEN CHAN |
分类号 |
A61K31/401;A61K38/08;A61K38/10;A61K38/17;A61K38/48;A61K38/49;A61K39/395;A61K45/06;(IPC1-7):A61K39/00;A01N61/00;A01N37/18 |
主分类号 |
A61K31/401 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|